dulaglutide

New diabetes drug set to rival TrulicityIf it is approved by FDA, an investigational drug to improve glycemic control in patients with type 2 diabetes will likely be a strong competitor to Eli Lilly’s dulaglutide (Trulicity).
Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
GLP-1 receptor more beneficial in reducing blood sugar compared to injectable therapy in Japanese patientsOnce-weekly dulaglutide is an effective treatment option for patients with type 2 diabetes who need to advance to injectable therapy, according to results from a Japanese study presented at the 2015 American Diabetes Association Scientific Sessions in Boston
New type 2 diabetes drug approved by FDAFDA has approved Trulicity (dulaglutide, Eli Lilly) to treat type 2 diabetes mellitus.
FDA approves once-weekly GLP-1 receptor agonist for type 2 diabetesFDA has approved dulaglutide (Trulicity, Eli Lilly) to treat type 2 diabetes mellitus. The drug is a once-weekly subcutaneous injection used to improve glycemic control and is indicated as an adjunct to diet and exercise in the management of type 2 diabetes in adults.
FDA drug approvals-September 2014FDA actions in brief, fast-track designations,priority review, orphan drug designations
ADA: Study says non-insulin dulaglutide demonstrates effective blood glucose control in diabetes patientsAmerican Diabetes Association Scientific Sessions in San Francisco, showed that investigational, non-insulin, once-weekly dulaglutide 1.5 mg provided significant blood glucose control for patients with type 2 diabetes.